Q1 EPS Estimate for Edwards Lifesciences Boosted by Analyst

Edwards Lifesciences Corporation (NYSE:EW) – Zacks Research lifted their Q1 2026 earnings per share estimates for shares of Edwards Lifesciences in a research report issued to clients and investors on Wednesday, August 13th. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $0.64 per share for the quarter, up from their prior estimate of $0.63. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q2 2026 earnings at $0.70 EPS, Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.74 EPS, Q2 2027 earnings at $0.77 EPS and FY2027 earnings at $3.11 EPS.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences’s revenue was up 11.9% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on the stock. Dbs Bank upgraded shares of Edwards Lifesciences to a “hold” rating in a research report on Monday, June 2nd. Wells Fargo & Company increased their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Mizuho boosted their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Stifel Nicolaus upped their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Finally, Canaccord Genuity Group raised their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.90.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $78.26 on Friday. The company’s fifty day moving average is $77.13 and its two-hundred day moving average is $74.41. The company has a market cap of $45.95 billion, a P/E ratio of 11.26, a price-to-earnings-growth ratio of 3.78 and a beta of 1.08. Edwards Lifesciences has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Insider Activity

In related news, VP Daveen Chopra sold 1,500 shares of the firm’s stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president directly owned 33,496 shares of the company’s stock, valued at $2,514,879.68. This trade represents a 4.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the sale, the insider owned 206,900 shares in the company, valued at $15,565,087. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,134 shares of company stock valued at $1,311,745 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its stake in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $49,038,000. Dynamic Advisor Solutions LLC grew its stake in shares of Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock worth $1,124,000 after purchasing an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after purchasing an additional 9,188 shares during the last quarter. Finally, Advanced Portfolio Management LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $328,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.